InvestSMART

Racura Oncology Ltd (ASX: RAC) - Announcements

Current share price for RAC : $1.950 0.1 (4.88%)+

ASX company news and announcements for Racura Oncology Ltd (RAC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Racura Oncology Ltd (RAC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Racura Oncology Ltd (RAC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Racura Oncology Ltd (RAC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$382 Appendix 3Y - Dr Daniel Tillett 23 Sep 2026 8:39AM $2.070 $1.950 fallen by 5.80%
$382 RC220 MYC-silencing data to be presented FCS 26 conference 8 Sep 2026 9:15AM $2.130 $1.950 fallen by 8.45%
$382 Racura Oncology Adelaide Investor Briefing 4 Sep 2026 9:57AM $2.140 $1.950 fallen by 8.88%
$382 Notification regarding unquoted securities - RAC 1 Sep 2026 1:15PM $2.210 $1.950 fallen by 11.76%
$382 CPACS Trial Opens for RC220 Patient Enrolment in Korea 1 Sep 2026 8:58AM $2.130 $1.950 fallen by 8.45%
$382 Corporate Governance Statement 25 Aug 2026 5:22PM $2.120 $1.950 fallen by 8.02%
$382 Appendix 4G 25 Aug 2026 5:21PM $2.120 $1.950 fallen by 8.02%
$382 Appendix 4E & Annual Report 25 Aug 2026 5:21PM $2.120 $1.950 fallen by 8.02%
$382 Racure Oncology Techknow Invest Presentation 29 Jul 2026 9:12AM $2.040 $1.950 fallen by 4.41%
$382 First HARNESS-1 Patient Safely Treated with RC220 29 Jul 2026 9:04AM $2.040 $1.950 fallen by 4.41%
$382 June 2026 Quarterly Activities Report and Appendix 4C 28 Jul 2026 9:12AM $2.070 $1.950 fallen by 5.80%
$382 Notification of cessation of securities - RAC 13 Jul 2026 8:57AM $2.190 $1.950 fallen by 10.96%
$382 Racura to Present CPACS Data at GCOS 2026 9 Jul 2026 10:42AM $2.130 $1.950 fallen by 8.45%
$382 Racura Oncology New Zealand Investor Events 6 Jul 2026 12:38PM $2.250 $1.950 fallen by 13.33%
$382 Bellberry Ethics Approval Activates New HARNESS Trial Sites 3 Jul 2026 8:46AM $2.280 $1.950 fallen by 14.47%
$382 Notification of cessation of securities - RAC 2 Jul 2026 8:29AM $2.200 $1.950 fallen by 11.36%
$382 Racura Treats First Patient in HARNESS-1 Lung Cancer Trial 25 Jun 2026 8:55AM $2.310 $1.950 fallen by 15.58%
$382 Racura Oncology Investor Briefings Perth & Auckland 16 Jun 2026 12:54PM $2.560 $1.950 fallen by 23.83%
$382 Racura raised $34.3m to Advance Three Oncology Trials 16 Jun 2026 12:36PM $2.320 $1.950 fallen by 15.95%
$382 Cleansing Notice 16 Jun 2026 12:33PM $2.320 $1.950 fallen by 15.95%
$382 Application for quotation of securities - RAC 16 Jun 2026 12:27PM $2.320 $1.950 fallen by 15.95%
$382 Cleansing Notice 11 Jun 2026 2:50PM $2.370 $1.950 fallen by 17.72%
$382 Application for quotation of securities - RAC 11 Jun 2026 2:49PM $2.310 $1.950 fallen by 15.58%
$382 Appendix 3Y-Dr Serge Scrofani 9 Jun 2026 8:48AM $2.700 $1.950 fallen by 27.78%
$382 Racura Options Raised $24.4m 4 Jun 2026 12:02PM $2.660 $1.950 fallen by 26.69%

1 - 25 of 996 results

Page 1 of 40

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.